Core Insights - On October 10, a total of 3,717 stocks in the A-share market received financing funds, with 560 stocks having a buying amount exceeding 100 million [1] - The top three stocks by financing buying amount were ZTE Corporation, Dongfang Wealth, and Newyeason, with amounts of 4.643 billion, 3.104 billion, and 2.867 billion respectively [1] - Two stocks had financing buying amounts accounting for over 30% of the total transaction amount, with Fengshen Co., Yuandong Bio, and Hongrun Construction leading at 35.77%, 31.62%, and 30.0% respectively [1] - A total of 45 stocks had a net financing buying amount exceeding 100 million, with Dongfang Wealth, ZTE Corporation, and WuXi AppTec ranking first, second, and third at 701 million, 623 million, and 586 million respectively [1] - The formation of a MACD golden cross signal indicates a positive trend for certain stocks [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688513 证券简称：苑东生物 公告编号：2025-073 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、已披露的增资暨关联交易概述 为加快公司创新转型战略的实施步伐，推动公司从仿制药向创新全面转型，公司分别于2025年9月23日 召开第四届董事会第八次会议、于2025年10月9日召开2025年第二次临时股东大会，审议通过了《关于 向参股公司增资暨关联交易的议案》，由公司全资子公司苑东生物投资管理（上海）有限公司（以下简 称"上海投资公司"）作为投资主体以货币资金的形式对上海超阳实施增资，增资价格为2.27元/注册资 本，增资总金额8,571.00万元（对应上海超阳注册资本3,771.00万元），资金来源均为自有资金。本次增 资完成后，上海超阳的注册资本将由原8,800.00万元增加至12,571.00万元，公司间接持有上海超阳的股 权比例将由30.68%增加至51.48%，上海超阳将变更为公司控股子公司，纳入公司合并报表范围。 具体内容详见公司于2025 ...

成都苑东生物制药股份有限公司 证券代码：688513 证券简称：苑东生物 公告编号：2025-073 关于向参股公司增资暨关联交易的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、已披露的增资暨关联交易概述 为加快公司创新转型战略的实施步伐，推动公司从仿制药向创新全面转型， 公司分别于 2025 年 9 月 23 日召开第四届董事会第八次会议、于 2025 年 10 月 9 日召开 2025 年第二次临时股东大会，审议通过了《关于向参股公司增资暨关联 交易的议案》，由公司全资子公司苑东生物投资管理（上海）有限公司（以下简 称"上海投资公司"）作为投资主体以货币资金的形式对上海超阳实施增资，增资 价格为 2.27 元/注册资本，增资总金额 8,571.00 万元（对应上海超阳注册资本 3,771.00 万元），资金来源均为自有资金。本次增资完成后，上海超阳的注册资 本将由原 8,800.00 万元增加至 12,571.00 万元，公司间接持有上海超阳的股权比 例将由 30.68%增加至 51.48%，上海超阳将 ...

Core Viewpoint - Yuan Dong Bio announced the election of Ms. Bo Xiaoqin as the employee representative director of the fourth board of directors during the first meeting of the fourth employee representative assembly [1] Summary by Categories - **Company Announcement** - Yuan Dong Bio held the first meeting of the fourth employee representative assembly [1] - Ms. Bo Xiaoqin was elected as the employee representative director [1]

证券代码：688513 证券简称：苑东生物 公告编号：2025-072 成都苑东生物制药股份有限公司 关于选举第四届董事会职工代表董事的公告 2025 年 10 月 10 日 1 附件：职工代表董事简介 伯小芹：女，1982 年 4 月生，中国国籍，中共党员，无境外永久居留权， 本科学历，会计学学士学位，中级会计师。2010 年 6 月至 2012 年 7 月先后任公 司成本会计/会计主管；2012 年 7 月至 2017 年 4 月任四川阳光润禾药业有限公司 财务经理；2017 年 4 月至 2017 年 10 月任销售财务副总监；2017 年 10 月至今任 公司总会计师，2022 年 10 月至今任公司财务总监，2024 年 12 月 27 日当选为公 司第四届董事会非独立董事。曾就职于江苏延申生物科技股份有限公司。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 成都苑东生物制药股份有限公司（以下称"公司"）于 2025 年 10 月 9 日召开 的 2025 年第二次临时股东大会审议通过了《关于取消监事会、修订< ...

证券代码：688513 证券简称：苑东生物 公告编号：2025-071 成都苑东生物制药股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 10 月 9 日 （二） 股东大会召开的地点：四川省成都市双流区安康路 8 号，苑东生物 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： 1、 公司在任董事9人，出席9人； 2、 公司在任监事3人，出席3人； 3、 公司董事会秘书现场出席本次会议；公司其他高级管理人员列席本次会议。 二、 议案审议情况 （一） 非累积投票议案 | 1、出席会议的股东和代理人人数 | 41 | | --- | --- | | 普通股股东人数 | 41 | | 2、出席会议的股东所持有的表决权数量 | 90,285,615 | | 普通股股东所持有表决权数量 | 90,285,615 | | 3、出席 ...

法律意见书 植德京(会)字[2025]0139 号 二〇二五年十月 北京市东城区东直门南大街 1 号来福士中心办公楼 12 层 邮编：100007 12th Floor, Raffles City Beijing Office Tower, No.1 Dongzhimen South Street, Dongcheng District, Beijing 100007 P.R.C 电话(Tel)：010-56500900 传真(Fax)：010-56500999 www.meritsandtree.com 北京植德律师事务所 关于成都苑东生物制药股份有限公司 2025 年第二次临时股东大会的 北京植德律师事务所 关于成都苑东生物制药股份有限公司 2025 年第二次临时股东大会的 法律意见书 植德京(会)字[2025]0139 号 致：成都苑东生物制药股份有限公司（贵公司） 北京植德律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出 席并见证贵公司 2025 年第二次临时股东大会（以下简称"本次会议"）。 本所律师参加本次会议进行见证，并根据《中华人民共和国公司法》（以下 简称"《公司法》"）、《中华人 ...

Core Viewpoint - Yuan Dong Bio is focusing on innovation-driven development in the biopharmaceutical sector, with a comprehensive industrial layout in chemical raw materials, high-end chemical drugs, and biological drugs [1] Summary by Relevant Sections Innovation Drug Development - The company has over 80 ongoing research projects, with innovative drug projects accounting for 24.4% of the total, including small molecule new drugs, biological drugs, and modified new drugs [1] - In the small molecule new drug category, the drug "Yoglitin Tablets" has achieved the expected goals in its Phase III clinical trial, while EP-0108 capsules, EP-0146 tablets, and EP-0186 tablets have received clinical trial approvals [1] - In the biological drug sector, the anesthetic and analgesic drug EP-9001A monoclonal antibody has completed Phase Ib clinical trials, and the ADC innovative drug YLSH003 has submitted an IND and received clinical approval [1] - Several modified new drugs, such as oral solution of chloral hydrate and extended-release oxycodone tablets, have been submitted for production, with multiple distinctive modified new drugs entering clinical stages [1] Strategic Investments and Collaborations - The company is actively tracking global cutting-edge technologies and accelerating its innovation transformation through strategic investments, external introductions, and collaborative development [1] - Following the acquisition of shares in Shanghai Chaoyang, the company's indirect shareholding increased from 11.36% to 30.68%, and it plans to further increase its stake to achieve controlling interest, raising its indirect ownership to 51.48% [1] - This strategic control over Shanghai Chaoyang will enhance the company's pipeline in frontier technology areas such as molecular glue, PROTAC (proteolysis-targeting chimeras), and DAC (drug-antibody conjugates), strengthening its R&D capabilities in innovative drugs [1]

Core Viewpoint - Chengdu Yuandong Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration of its drug, Ethyl Pheylbutazone Tablets, marking a significant milestone for the company in the pharmaceutical market [1][2]. Drug Basic Information - Drug Name: Ethyl Pheylbutazone Tablets - Dosage Form: Tablets - Specification: 50mg - Registration Category: Chemical Drug Class 4 - Validity Period: 18 months - Holder of Marketing Authorization: Chengdu Shode Pharmaceutical Co., Ltd. - Production Company: Chengdu Shode Pharmaceutical Co., Ltd. - Registration Standard Number: YBH23792025 - Acceptance Number: CYHS2402415 - Certificate Number: 2025S02973 - Approval Document Number: Guoyao Zhunzi H20255554 - Approval Conclusion: The drug meets the registration requirements as per the relevant laws and regulations [1]. Drug Indications and Market Context - The primary active ingredient is Ethyl Pheylbutazone, indicated for conditions such as cervical, shoulder, and lumbar pain, as well as various spastic paralysis conditions [2]. - The drug was originally developed by Eisai Co., Ltd. in Japan and was first approved for sale in Japan in February 1983, later imported to China in July 2004 [2]. - It is classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Directory (2024) [2]. - The drug is the first generic drug approved under the new registration classification, equivalent to passing the consistency evaluation [2]. - Sales data from major public hospitals indicate that the expected sales for Ethyl Pheylbutazone Tablets in 2024 are approximately 102.61 million yuan, reflecting a year-on-year growth of 14.01% [2]. Impact on the Company - The approval of Ethyl Pheylbutazone Tablets signifies that the product meets the necessary registration requirements, although it is not expected to have a significant impact on the company's short-term performance [3]. - The period from approval to market production may face uncertainties, and the company will fulfill its information disclosure obligations as required by law [3].

Core Viewpoint - Chengdu Yuandong Pharmaceutical Co., Ltd. has received the drug registration certificate for its product, Hydrochloride Ephedrine Tablets, marking a significant milestone in its product portfolio and compliance with regulatory standards [1][2]. Drug Basic Information - Drug Name: Hydrochloride Ephedrine Tablets - Dosage Form: Tablets - Specification: 50mg - Registration Category: Class 4 Chemical Drug - Validity Period: 18 months - Holder of Marketing Authorization: Chengdu Shuo De Pharmaceutical Co., Ltd. - Production Company: Chengdu Shuo De Pharmaceutical Co., Ltd. - Drug Registration Standard Number: YBH23792025 - Approval Conclusion: The product meets the requirements for drug registration and has been granted a registration certificate [1][2]. Drug Indications - Hydrochloride Ephedrine Tablets are indicated for: 1. Improving muscle tension in conditions such as cervical shoulder-arm syndrome, periarthritis of the shoulder, and low back pain 2. Spastic paralysis caused by cerebrovascular disorders, spastic myelopathy, cervical spondylosis, postoperative sequelae, traumatic sequelae, amyotrophic lateral sclerosis, infantile cerebral palsy, and other spinal cord diseases [2]. Market Performance - The sales amount for Hydrochloride Ephedrine Tablets in public hospitals in key provinces and cities is projected to be approximately 102.61 million yuan in 2024, reflecting a year-on-year growth of 14.01% [3]. Impact on the Company - The approval of Hydrochloride Ephedrine Tablets signifies that the product meets the necessary registration requirements and is considered to have passed the consistency evaluation. However, it is noted that the approval will not have a significant impact on the company's short-term performance [4].